简报:RET酪氨酸激酶抑制剂治疗期间发生的乳糜胸与乳糜腹水
此项多中心回顾性研究评估RET酪氨酸激酶抑制剂治疗患者乳糜性积液的频率,分析全癌种队列7517例及选择性TKI队列96例。乳糜性积液最常见于selpercatinib(7%),其次为agerafenib(4%)、cabozantinib(0.3%)和lenvatinib(0.02%),pralsetinib未见。22例积液中13%检出恶性细胞,淋巴管造影未发现乳糜漏。
要点
- selpercatinib治疗者乳糜性积液发生率7%,agerafenib为4%,cabozantinib为0.3%,lenvatinib为0.02%,pralsetinib未见。
- 乳糜胸积液甘油三酯中位数397 mg/dL,乳糜腹水3786 mg/dL,两者比较p=0.035。
- 初始引流后,76%乳糜胸和80%乳糜腹水患者需额外干预。
核心结论
- 选择性RET酪氨酸激酶抑制剂治疗期间可出现乳糜性积液,识别此副作用对避免将积液恶化误归因于恶性肿瘤进展至关重要。
研究设计与样本
- 多中心回顾性研究,分析全癌种队列7517例接受一种或多种多激酶抑制剂或选择性RET TKI治疗的患者,以及选择性TKI队列96例接受selpercatinib或pralsetinib治疗的患者。
主要发现
- 乳糜性积液最常见于selpercatinib(7%),其次为agerafenib(4%)、cabozantinib(0.3%)、lenvatinib(0.02%),pralsetinib未见。
- 共12例发生乳糜胸,5例发生乳糜腹水,5例两者均有。
- 从TKI开始至诊断时间范围为0.5至50个月。
- 乳糜胸积液甘油三酯中位水平低于乳糜腹水(397 mg/dL [四分位距:304-4000] 对 3786 mg/dL [四分位距:842-6596],p=0.035)。
- 22例积液中13%(3/22)检出恶性细胞;淋巴管造影未发现乳糜漏。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Spontaneous chylous effusions are rare; however, they have been observed by independent investigators in patients treated with RET tyrosine kinase inhibitors (TKIs). METHODS: This multicenter, retrospective study evaluated the frequency of chylous effusions in patients treated with RET TKIs. Clinicopathologic features and management of patients with chylous effusions were evaluated. RESULTS: A pan-cancer cohort of 7517 patients treated with one or more multikinase inhibitor or selective RET TKI and a selective TKI cohort of 96 patients treated with selpercatinib or pralsetinib were analyzed. Chylous effusions were most common with selpercatinib (7%), followed by agerafenib (4%), cabozantinib (0.3%), and lenvatinib (0.02%); none were observed with pralsetinib. Overall, 12 patients had chylothorax, five had chylous ascites, and five had both. Time from TKI initiation to diagnosis ranged from 0.5 to 50 months. Median fluid triglyceride level was lower in chylothoraces than in chylous ascites (397 mg/dL [interquartile range: 304-4000] versus 3786 mg/dL [interquartile range: 842-6596], p = 0.035). Malignant cells were present in 13% (3 of 22) of effusions. Chyle leak was not identified by lymphangiography. After initial drainage, 76% of patients with chylothorax and 80% with chylous ascites required additional interventions. Selpercatinib dose reduction and discontinuation rates in those with chylous effusions were 47% and 0%, respectively. Median time from diagnosis to disease progression was not reached (95% confidence interval: 14.5-undefined); median time from diagnosis to TKI discontinuation was 11.4 months (95% confidence interval: 8.2-14.9). CONCLUSIONS: Chylous effusions can emerge during treatment with selected RET TKIs. Recognition of this side effect is key to prevent potential misattribution of worsening effusions to progressive malignancy.
引用
- Kalchiem-Dekel O, Falcon CJ, Bestvina CM, et al. Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. J Thorac Oncol. 2022. PMID: 35788405. doi:10.1016/j.jtho.2022.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。